Company Filing History:
Years Active: 2002
Title: The Innovations of Jane Hogeland in Antineoplastic Agents
Introduction
Jane Hogeland, an accomplished inventor based in Woburn, MA, is recognized for her contributions to the field of pharmaceuticals, specifically in the synthesis of antineoplastic agents. With a singular yet significant patent to her name, Hogeland has made noteworthy strides in cancer research, showcasing innovation and expertise.
Latest Patents
Hogeland's patent is titled "Synthesis of β-lapachone and its intermediates." This groundbreaking process focuses on synthesizing β-lapachone, a compound with demonstrated antineoplastic activity against human cancer lines. The synthesis involves a clever conversion of the starting material, 2-hydroxy-1,4-naphthoquinone, into the β-lapachone intermediate called lapachol. After the formation of lapachol, it is converted to β-lapachone through treatment with sulfuric acid and subsequently purified by recrystallization from ethanol. This novel process not only simplifies the synthesis but also ensures excellent quality and high yield of β-lapachone, making it a valuable contribution to cancer therapeutics.
Career Highlights
Hogeland has been a vital part of Cyclis Pharmaceuticals, Inc., where she applies her knowledge and skills to push the boundaries of pharmaceutical innovation. Her focus on developing efficient synthesis methods reflects her dedication to enhancing drug availability and effectiveness in cancer treatment.
Collaborations
In her professional journey, Jane Hogeland has collaborated with Zhiwei Jiang, demonstrating the importance of teamwork in the field of research and development. Their combined expertise likely fosters an environment of innovation and drives the advancement of their projects at Cyclis Pharmaceuticals.
Conclusion
Jane Hogeland's contributions as an inventor, particularly her patented work on the synthesis of β-lapachone, underscore the importance of innovation in cancer research. Her role at Cyclis Pharmaceuticals, alongside collaborative efforts with colleagues like Zhiwei Jiang, highlights her commitment to advancing pharmaceutical sciences for better health outcomes. As research continues, Hogeland's work will undoubtedly inspire further innovations in the battle against cancer.